However, exaggerated RAAS activation in portal hypertension leads to many dreadful complications such as ascites’ formation and hepatorenal syndrome, which has raised the therapeutic application of RAAS inhibitors, such as angiotensin converting enzyme inhibitor, angiotensin receptor blocker (ARB), and direct renin inhibitor [3,4]. Here, REN is linked to portal hypertension.